Matinas Biopharma (MTNB) Competitors $0.91 -0.03 (-2.87%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.91 -0.01 (-0.55%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. IMNN, LPCN, CING, LEXX, MRKR, PMN, CASI, HOTH, CLRB, and CGTXShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Imunon (IMNN), Lipocine (LPCN), Cingulate (CING), Lexaria Bioscience (LEXX), Marker Therapeutics (MRKR), Promis Neurosciences (PMN), CASI Pharmaceuticals (CASI), Hoth Therapeutics (HOTH), Cellectar Biosciences (CLRB), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors Imunon Lipocine Cingulate Lexaria Bioscience Marker Therapeutics Promis Neurosciences CASI Pharmaceuticals Hoth Therapeutics Cellectar Biosciences Cognition Therapeutics Matinas Biopharma (NYSE:MTNB) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Does the media refer more to MTNB or IMNN? In the previous week, Imunon had 4 more articles in the media than Matinas Biopharma. MarketBeat recorded 4 mentions for Imunon and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Imunon's score of -0.02 indicating that Matinas Biopharma is being referred to more favorably in the media. Company Overall Sentiment Matinas Biopharma Neutral Imunon Neutral Which has more volatility and risk, MTNB or IMNN? Matinas Biopharma has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Imunon has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Is MTNB or IMNN more profitable? Matinas Biopharma's return on equity of -123.06% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Imunon N/A -427.98%-175.03% Do analysts rate MTNB or IMNN? Imunon has a consensus target price of $15.50, suggesting a potential upside of 1,859.54%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has stronger valuation & earnings, MTNB or IMNN? Imunon has higher revenue and earnings than Matinas Biopharma. Imunon is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.86-0.24Imunon$500K27.75-$18.62M-$1.36-0.58 Do institutionals and insiders have more ownership in MTNB or IMNN? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Comparatively, 6.0% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryImunon beats Matinas Biopharma on 10 of the 15 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.67M$812.97M$5.55B$20.71BDividend YieldN/A4.84%5.22%3.71%P/E Ratio-0.191.3727.6628.08Price / SalesN/A228.55418.7238.37Price / CashN/A23.4436.8922.53Price / Book0.216.328.034.58Net Income-$22.94M-$27.99M$3.18B$985.54M7 Day Performance-0.77%2.10%2.93%2.79%1 Month Performance-1.82%9.39%1.72%4.37%1 Year PerformanceN/A11.51%34.39%15.08% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.91-2.9%N/AN/A$4.67MN/A-0.1930IMNNImunon2.0969 of 5 stars$0.92-9.6%$15.50+1,581.5%-41.8%$17.89M$500K-0.6830News CoverageAnalyst UpgradeLPCNLipocine1.5974 of 5 stars$3.14-4.8%$9.00+186.6%-55.1%$17.66M$11.20M-3.0810CINGCingulate2.3083 of 5 stars$4.04-2.4%$26.00+543.6%+1,157.3%$17.58MN/A-0.4820Positive NewsLEXXLexaria Bioscience2.8531 of 5 stars$0.97+0.7%$7.00+623.8%-67.2%$16.86M$460K-1.647News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionMRKRMarker Therapeutics3.2099 of 5 stars$1.42-2.1%$13.17+827.2%-68.3%$16.41M$6.59M-1.0760Positive NewsGap UpPMNPromis Neurosciences3.3942 of 5 stars$0.47-6.0%$4.50+857.2%-74.1%$16.34MN/A-9.405Gap UpCASICASI Pharmaceuticals4.1211 of 5 stars$1.23-7.2%$4.00+225.2%-76.8%$16.30M$28.54M-0.48180Positive NewsHOTHHoth Therapeutics1.4362 of 5 stars$1.23+1.2%$4.00+226.5%+38.5%$15.98MN/A-1.074Analyst UpgradeGap DownCLRBCellectar Biosciences3.3085 of 5 stars$0.30+2.1%$12.50+4,097.4%-93.3%$15.86MN/A-0.4110Gap UpHigh Trading VolumeCGTXCognition Therapeutics2.7894 of 5 stars$0.26+1.8%$5.63+2,067.6%-76.2%$15.81MN/A-0.3520News CoverageGap Up Related Companies and Tools Related Companies IMNN Alternatives LPCN Alternatives CING Alternatives LEXX Alternatives MRKR Alternatives PMN Alternatives CASI Alternatives HOTH Alternatives CLRB Alternatives CGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTNB Stock Alerts